Last reviewed · How we verify

NCT04263701

Dual Task Training in Spastic Cerebral Palsy

Completed NA Last updated 23 March 2021
What this trial tests

NA trial testing Therapeutic exercises in Cerebral Palsy in 10 participants. Completed in 15 March 2020.

Timeline
1 July 2019
Primary endpoint
15 March 2020
15 March 2020

Quick facts

Lead sponsorKutahya Health Sciences University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment10
Start date1 July 2019
Primary completion15 March 2020
Estimated completion15 March 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Kutahya Health Sciences University

Who can join

Adults 7 to 16, any sex, with Cerebral Palsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the effects of dual task training on gait and balance parameters, gross motor function skills, functional mobility skills, functional independence levels and health-related quality of life o in children with spastic diplegic cerebral palsy. The clinical study's hypothesis is the dual task training programs are superior to conventional physiotherapy programs to improve the parameters in spastic diplegic cerebral palsy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Therapeutic exercises

Trials testing the same drug.

Other recruiting trials for Cerebral Palsy

Currently open trials in the same condition.

Other Kutahya Health Sciences University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04263701.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing